论文部分内容阅读
目的探讨紫杉醇联合卡铂及榄香烯乳注射液(ETC)化疗方案治疗晚期非小细胞肺癌(NSCLC)的疗效。方法 80例NSCLC晚期患者随机分为治疗组与对照组,各40例,治疗组给予ETC方案化疗;对照组仅给予TC方案化疗。所有患者每周期评价不良反应及KPS评分改善情况,每2周期后评价疗效。对治疗后两组患者的近期疗效、不良反应、生活质量改善进行组间比较。结果治疗组在近期疗效及KPS评分改善、肺癌相关症状控制方面均优于对照组(P<0.05)。不良反应:白细胞减少发生率治疗组Ⅰ~Ⅱ度为37.5%,Ⅲ~Ⅳ度为12.5%,对照组分别为40.0%和17.5%,两组比较差异具有统计学意义(P<0.05)。两组血小板减少及胃肠道反应比较,差异无统计学意义(P>0.05)。结论榄香烯联合紫杉醇及卡铂化疗方案在提高疗效同时改善了患者一般状况,提高了生活质量,疗效确切,值得在临床推广。
Objective To investigate the efficacy of paclitaxel combined with carboplatin and elemene injection (ETC) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Eighty patients with advanced NSCLC were randomly divided into treatment group and control group, 40 cases in each group. ETC regimen chemotherapy was given in the treatment group and TC regimen was given in the control group. All patients were evaluated every week to improve the adverse reaction and KPS score, evaluate the efficacy after every 2 cycles. The two groups of patients after treatment, the short-term efficacy, adverse reactions, quality of life improved compared between groups. Results The treatment group was better than the control group in the short term curative effect and improvement of KPS score and lung cancer related symptoms (P <0.05). Adverse reactions: The incidence of leukopenia was 37.5% in the treatment group, 12.5% in the third to fourth degree and 40.0% and 17.5% in the control group, respectively. There was significant difference between the two groups (P <0.05). There was no significant difference between the two groups in thrombocytopenia and gastrointestinal reaction (P> 0.05). Conclusion Elemene combined with paclitaxel and carboplatin chemotherapy in improving the efficacy of the same time improve the general condition of patients and improve the quality of life, curative effect is exact, it is worth in the clinical promotion.